For so many advances in medical technology, Synlogic, an MIT spinout company announced the synthetic biotics development that could track and fix abnormalities at a metabolic level.
There are currently two drugs that are set to begin clinical trials, one is for so called urea cycle disorder (UCD) an enzyme deficiency that causes ammonia buildup in the blood and the other one is for (PKU) phenylketonuria where a metabolic enzyme mutation causes excessive phenylalanine. It certainly describes that these drugs are designed to take away toxic metabolites from the body.
The main focus on this challenge is to find the right dosage of the said drugs to determine the positive effects on the immune system.
The study could also be applied for treatment of other serious conditions from cardiovascular to nervous system disorders.